Literature DB >> 10994476

Regression in skin tumours: a common phenomenon.

R S Barnetson1, G M Halliday.   

Abstract

Regression in epithelial skin tumours is a common phenomenon, and this may be partial or complete. In keratoacanthoma and familial self-healing epithelioma, nearly all the tumours regress completely. The incidence of total regression in melanoma and basal cell carcinoma is unknown, but in 25% of melanomas and 50% of basal cell carcinomas there is evidence of partial regression on histological examination. Previous studies carried out in our laboratories have indicated that regression of skin tumours is likely to be mediated by activated CD4+ T lymphocytes, possibly via cytokine secretion.

Entities:  

Mesh:

Year:  1997        PMID: 10994476     DOI: 10.1111/j.1440-0960.1997.tb01013.x

Source DB:  PubMed          Journal:  Australas J Dermatol        ISSN: 0004-8380            Impact factor:   2.875


  15 in total

1.  'The nodule that disappeared' spontaneous regression of an eyelid noduloulcerative lesion mimicking the features of a basal cell carcinoma.

Authors:  Tafadzwa Young-Zvandasara; Magdalena Popiela; Garry Shuttleworth
Journal:  BMJ Case Rep       Date:  2015-01-29

2.  A new animal model for the imaging of melanoma: correlation of FDG PET with clinical outcome, macroscopic aspect and histological classification in Melanoblastoma-bearing Libechov Minipigs.

Authors:  Raphaël Boisgard; Silvia Vincent-Naulleau; Jean-Jacques Leplat; Stephan Bouet; Catherine Le Chalony; Yves Tricaud; Vratislav Horak; Claudine Geffrotin; Gérard Frelat; Bertrand Tavitian
Journal:  Eur J Nucl Med Mol Imaging       Date:  2003-04-08       Impact factor: 9.236

Review 3.  Combining cytotoxic and immune-mediated gene therapy to treat brain tumors.

Authors:  James F Curtin; Gwendalyn D King; Marianela Candolfi; Remy B Greeno; Kurt M Kroeger; Pedro R Lowenstein; Maria G Castro
Journal:  Curr Top Med Chem       Date:  2005       Impact factor: 3.295

4.  The neuropeptide alpha-melanocyte-stimulating hormone is critically involved in the development of cytotoxic CD8+ T cells in mice and humans.

Authors:  Karin Loser; Thomas Brzoska; Vinzenz Oji; Matteo Auriemma; Maik Voskort; Verena Kupas; Lars Klenner; Cornelius Mensing; Axel Hauschild; Stefan Beissert; Thomas A Luger
Journal:  PLoS One       Date:  2010-02-01       Impact factor: 3.240

5.  Characterization of three newly established rat sarcoma cell clones.

Authors:  Monika Holubova; Martin Leba; Markéta Sedmikova; Luca Vannucci; Vratislav Horak
Journal:  In Vitro Cell Dev Biol Anim       Date:  2012-11-13       Impact factor: 2.416

6.  Skin Cancer Risk Is Modified by KIR/HLA Interactions That Influence the Activation of Natural Killer Immune Cells.

Authors:  Karin A Vineretsky; Margaret R Karagas; Brock C Christensen; Jacquelyn K Kuriger-Laber; Ann E Perry; Craig A Storm; Heather H Nelson
Journal:  Cancer Res       Date:  2016-01-07       Impact factor: 12.701

7.  Gene expression signature for spontaneous cancer regression in melanoma pigs.

Authors:  Florian Rambow; Guillaume Piton; Stephan Bouet; Jean-Jaques Leplat; Sylvain Baulande; Angelique Marrau; Mark Stam; Vratislav Horak; Silvia Vincent-Naulleau
Journal:  Neoplasia       Date:  2008-07       Impact factor: 5.715

8.  Regression of Periocular Basal Cell Carcinoma: A Report of Four Cases with Clinicopathologic Correlation.

Authors:  Martina C Herwig-Carl; Karin U Loeffler
Journal:  Ocul Oncol Pathol       Date:  2019-08-28

9.  Influence of genetic variants in type I interferon genes on melanoma survival and therapy.

Authors:  Romina Elizabeth Lenci; Melanie Bevier; Andreas Brandt; Justo Lorenzo Bermejo; Antje Sucker; Iris Moll; Dolores Planelles; Celia Requena; Eduardo Nagore; Kari Hemminki; Dirk Schadendorf; Rajiv Kumar
Journal:  PLoS One       Date:  2012-11-27       Impact factor: 3.240

10.  Carcinoma-like vascular density in atypic keratoacanthoma suggests malignant progression.

Authors:  S Strieth; W Hartschuh; L Pilz; N E Fusenig
Journal:  Br J Cancer       Date:  2002-11-18       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.